See more : RH (0KTF.L) Income Statement Analysis – Financial Results
Complete financial analysis of PPD, Inc. (PPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PPD, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Coaster International Co., Ltd. (2936.TW) Income Statement Analysis – Financial Results
- Suzuyo Shinwart Corporation (9360.T) Income Statement Analysis – Financial Results
- Super Spinning Mills Limited (SUPERSPIN.NS) Income Statement Analysis – Financial Results
- Trilogy International Partners Inc. (TLLYF) Income Statement Analysis – Financial Results
- Atlas Copco AB (ATCO-A.ST) Income Statement Analysis – Financial Results
PPD, Inc. (PPD)
About PPD, Inc.
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 4.68B | 4.03B | 3.75B | 3.00B | 2.68B |
| Cost of Revenue | 2.88B | 2.41B | 2.27B | 1.54B | 1.39B |
| Gross Profit | 1.80B | 1.62B | 1.47B | 1.46B | 1.29B |
| Gross Profit Ratio | 38.42% | 40.24% | 39.32% | 48.80% | 48.25% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
| Operating Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
| Cost & Expenses | 4.17B | 3.61B | 3.35B | 2.74B | 2.37B |
| Interest Income | 0.00 | 0.00 | 5.45M | 3.55M | 2.51M |
| Interest Expense | 216.93M | 311.74M | 263.62M | 253.89M | 203.29M |
| Depreciation & Amortization | 279.12M | 264.83M | 258.97M | 279.07M | 260.49M |
| EBITDA | 668.54M | 627.35M | 666.36M | 544.62M | 630.92M |
| EBITDA Ratio | 14.28% | 15.56% | 17.77% | 18.15% | 23.55% |
| Operating Income | 509.43M | 418.49M | 402.24M | 261.33M | 314.26M |
| Operating Income Ratio | 10.88% | 10.38% | 10.73% | 8.71% | 11.73% |
| Total Other Income/Expenses | -321.88M | -359.21M | -255.61M | -244.86M | -147.37M |
| Income Before Tax | 187.55M | 59.28M | 146.63M | 16.47M | 166.89M |
| Income Before Tax Ratio | 4.01% | 1.47% | 3.91% | 0.55% | 6.23% |
| Income Tax Expense | 18.81M | 2.96M | 39.58M | -284.36M | -15.96M |
| Net Income | 153.69M | 47.82M | 104.19M | 296.03M | 183.10M |
| Net Income Ratio | 3.28% | 1.19% | 2.78% | 9.86% | 6.83% |
| EPS | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
| EPS Diluted | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
| Weighted Avg Shares Out | 346.68M | 339.43M | 324.30M | 325.04M | 324.22M |
| Weighted Avg Shares Out (Dil) | 346.68M | 339.43M | 324.30M | 325.86M | 324.30M |
PPD Named ‘Most Innovative CRO’ by Triangle Business Journal
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) has been named “Most Innovative CRO” by North Carolina’s Triangle Business Journal, recognizing the global contract research organization’s strong performance in a year shaped by the COVID-19 pandemic. PPD’s significant investments to expand capabilities...
PPD Opens Multipurpose Clinical Research Laboratory in Suzhou, China
SUZHOU, China--(BUSINESS WIRE)--PPD held a grand opening event for its new multipurpose lab in Suzhou, China, to support pharma and biotech companies managing China research studies
PPD Opens Multipurpose Clinical Research Laboratory in Suzhou, China
SUZHOU, China--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, held a grand opening ceremony for its new multipurpose laboratory in Suzhou, China, to support Western and China-based pharmaceutical and biotech companies managing China research studies. The 67,000-square-foot...
CRO Leadership Awards Recognize PPD for Excellence for 10th Consecutive Year
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD has been recognized for excellence in the CRO Leadership Awards, earning praise for its clinical research capabilities and customer compatibility.
CRO Leadership Awards Recognize PPD for Excellence for 10th Consecutive Year
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) has been recognized for excellence in the CRO Leadership Awards for the 10th consecutive year, earning praise for its clinical research capabilities and customer compatibility in a survey of pharmaceutical and biotech professionals conducted...
SHAREHOLDER ALERT: WeissLaw LLP Reminds WRI, PPD, VKIN, and GNBF Shareholders About Its Ongoing Investigations
NEW YORK, May 13, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua...
PPD Named “Best CRO” at Vaccine Industry Excellence Awards
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) was named “Best Contract Research Organization” at the 14th annual Vaccine Industry Excellence (ViE) Awards during the 2021 World Vaccine Congress. Accelerated Enrollment Solutions (AES), a business of PPD, received the honor of “highly...
PPD Named “Best CRO” at Vaccine Industry Excellence Awards
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD was named “Best Contract Research Organization” at the 14th annual Vaccine Industry Excellence Awards during the 2021 World Vaccine Congress
PPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, is expanding its Athlone, Ireland, GMP (good manufacturing practices) laboratory, significantly increasing the size of its current facility and adding cell and gene therapy testing to the operation’s...
PPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD is expanding its Athlone, Ireland, GMP (good manufacturing practices) laboratory
Source: https://incomestatements.info
Category: Stock Reports